Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZD8586 in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
CTR20220558Phase 2Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of birelentinib in mature B-cell lymphoma, central nervous system lymphoma, sponsored by Dizal Pharmaceutical Co., Ltd.. Started Mar 2022; status: completed.
02
Drugs
birelentinib
03
Conditions
mature B-cell lymphomacentral nervous system lymphoma
Beyond the preview
Go deeper on CTR20220558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220558.